ArticleCancer discovery2017
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04720131 (Camrelizumab Combined With Apatinib and Capecitabine for Patients With Advanced Biliary Tract Cancer), which is not on this map. Cited by 539 papers.
0numbers the graph read from it
0cells of the map it votes in
539citing papers in PubMed
59.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Camrelizumab Combined With Apatinib and Capecitabine for Patients With Advanced Biliary Tract Cancer: a Phase 2, Single-arm, Prospective Study.
Who cites it
539 citing papers in PubMed, 958 citations in OpenAlex.
- Assessment of MRD and Longitudinal Monitoring of Post-Surgery Biliary Tract Cancer With a Customized ctDNA Panel.Cancer science · 2026Article
- Cholangiocarcinoma:Unveiling the cold tumor microenvironment and strategies for immune rejuvenation.Oncogene · 2026Review
- Hepatitis B virus pregenomic RNA is associated with malignant phenotypes and postoperative survival in HBV-related intrahepatic cholangiocarcinoma.Infectious agents and cancer · 2026Article
- Clinical benefit of adjuvant chemotherapy in resected T2N0 distal cholangiocarcinoma: a retrospective cohort study.Annals of surgical treatment and research · 2026Article
- Metabolic and Inflammatory Risk Stratification in Resected Cholangiocarcinoma: A Retrospective Exploratory Analysis.Medical sciences (Basel, Switzerland) · 2026Article
- Article
- Decoding the cholangiocarcinoma tumor microenvironment: from single-cell and spatial atlases to translational therapeutic targeting.Journal of translational medicine · 2026Review
- Global patterns of mutational profiles in biliary tract cancer.Journal of hepatology · 2026Article
- Using cell-free DNA tumor methylation score to detect and monitor cholangiocarcinoma.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2026Article
- Prognostic, Predictive, and Clinical Relevance of DNA Damage Repair Alterations in Biliary Tract Cancers.Cancers · 2026Review
- Role of the stromal and immune microenvironment in intrahepatic cholangiocarcinoma.JHEP reports : innovation in hepatology · 2026Review
- The Evolving Landscape of Immune Regulation and Immunotherapy in Cholangiocarcinoma and Biliary Tract Cancer.Cancers · 2026Review
- Article
- Aquaporin-1 differentiates intrahepatic cholangiocarcinoma from liver metastases of pancreatic ductal adenocarcinoma.Histopathology · 2026Article
- Article
- Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in TP53-mutated advanced biliary tract cancer.Journal of gastroenterology · 2026Article
- The allosteric IDH1 inhibitor ivosidenib overcomes chemoresistance in intrahepatic cholangiocarcinoma models expressing wild-type IDH1.The Journal of clinical investigation · 2026Article
- ELOVL1 promotes the progression of intrahepatic cholangiocarcinoma by enhancing endoplasmic reticulum stress and the PI3K/AKT/mTOR signaling pathway.Biology direct · 2026Article
- Deep molecular profiling of biliary tract cancer uncovers novel biological mechanisms and therapeutic opportunities.ESMO open · 2026Article
- EGR1 lactylation induces tumor cell senescence and immunosuppressive microenvironment in intrahepatic cholangiocarcinoma.Translational oncology · 2026Article
479 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
58 authors at 19 institutions in 12 countries.
Apinya JusakulProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore.
Ioana CutcutacheCentre for Computational Biology, Duke-NUS Medical School, Singapore.
Chern Han YongProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore.
Jing Quan LimLaboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
Mi Ni HuangCentre for Computational Biology, Duke-NUS Medical School, Singapore.
Nisha PadmanabhanProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore.
Vishwa NelloreDepartment of Biostatistics and Bioinformatics, Center for Genomic and Computational Biology, Duke University, Durham, North Carolina.
Sarinya KongpetchLaboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
Alvin Wei Tian NgNUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore.
Ley Moy NgCancer Science Institute of Singapore, National University of Singapore, Singapore.
Su Pin ChooDivision of Medical Oncology, National Cancer Centre Singapore, Singapore.
Swe Swe MyintLaboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
Raynoo ThananDepartment of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Sanjanaa NagarajanLaboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
Weng Khong LimProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore.
Cedric Chuan Young NgLaboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
Arnoud BootProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore.
Mo LiuProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore.
Choon Kiat OngLymphoma Genomic Translational Research Laboratory, National Cancer Centre Singapore, Division of Medical Oncology, Singapore.
Vikneswari RajasegaranLaboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
Stefanus LieLaboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
Alvin Soon Tiong LimCytogenetics Laboratory, Department of Molecular Pathology, Singapore General Hospital, Singapore.
Tse Hui LimCytogenetics Laboratory, Department of Molecular Pathology, Singapore General Hospital, Singapore.
Jing TanLaboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
Jia Liang LohLaboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
John R McPhersonCentre for Computational Biology, Duke-NUS Medical School, Singapore.
Narong KhuntikeoCholangiocarcinoma Screening and Care Program and Liver Fluke and Cholangiocarcinoma Research Centre, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Vajaraphongsa BhudhisawasdiDepartment of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Puangrat YongvanitCholangiocarcinoma Screening and Care Program and Liver Fluke and Cholangiocarcinoma Research Centre, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Sopit WongkhamDepartment of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Yasushi TotokiDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Hiromi NakamuraDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Yasuhito AraiDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Satoshi YamasakiLaboratory of Molecular Medicine, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Japan.
Pierce Kah-Hoe ChowDivision of Surgical Oncology, National Cancer Center Singapore and Office of Clinical Sciences, Duke-NUS Medical School, Singapore.
Alexander Yaw Fui ChungDepartment of Hepatopancreatobiliary/Transplant Surgery, Singapore General Hospital, Singapore.
London Lucien Peng Jin OoiDepartment of Hepatopancreatobiliary/Transplant Surgery, Singapore General Hospital, Singapore.
Kiat Hon LimDepartment of Anatomical Pathology, Singapore General Hospital, Singapore.
Simona DimaCenter of Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania.
Dan G DudaEdwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Irinel PopescuCenter of Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania.
Philippe BroetDHU Hepatinov, Hôpital Paul Brousse, AP-HP, Villejuif, France.
Sen-Yung HsiehDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan.
Ming-Chin YuDepartment of General Surgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan.
Aldo ScarpaApplied Research on Cancer Centre (ARC-Net), University and Hospital Trust of Verona, Verona, Italy.
Jiaming LaiDepartment of Hepatobiliary Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, P. R. China.
Di-Xian LuoNational and Local Joint Engineering Laboratory of High-through Molecular Diagnostic Technology, the First People's Hospital of Chenzhou, Southern Medical University, Chenzhou, P. R. China.
André Lopes CarvalhoBarretos Cancer Hospital, Barretos, São Paulo, Brazil.
André Luiz VettoreLaboratory of Cancer Molecular Biology, Department of Biological Sciences, Federal University of São Paulo, Rua Pedro de Toledo, São Paulo, Brazil.
Hyungjin RheeDepartment of Pathology, Brain Korea 21 PLUS Project for Medical Science, Integrated Genomic Research Center for Metabolic Regulation, Yonsei University College of Medicine, Seoul, Korea.
Young Nyun ParkDepartment of Pathology, Brain Korea 21 PLUS Project for Medical Science, Integrated Genomic Research Center for Metabolic Regulation, Yonsei University College of Medicine, Seoul, Korea.
Ludmil B AlexandrovTheoretical Biology and Biophysics (T-6), Los Alamos National Laboratory, and Center for Nonlinear Studies, Los Alamos National Laboratory, Los Alamos, New Mexico.
Raluca GordânDepartment of Biostatistics and Bioinformatics, Center for Genomic and Computational Biology, Duke University, Durham, North Carolina. gmstanp@duke-nus.edu.sg teh.bin.tean@singhealth.com.sg chawalit-pjk2011@hotmail.com tashibat@ncc.go.jp steve.rozen@duke-nus.edu.sg raluca.gordan@duke.edu.
Steven G RozenProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore. gmstanp@duke-nus.edu.sg teh.bin.tean@singhealth.com.sg chawalit-pjk2011@hotmail.com tashibat@ncc.go.jp steve.rozen@duke-nus.edu.sg raluca.gordan@duke.edu.
Tatsuhiro ShibataDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan. gmstanp@duke-nus.edu.sg teh.bin.tean@singhealth.com.sg chawalit-pjk2011@hotmail.com tashibat@ncc.go.jp steve.rozen@duke-nus.edu.sg raluca.gordan@duke.edu.
Chawalit PairojkulDepartment of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. gmstanp@duke-nus.edu.sg teh.bin.tean@singhealth.com.sg chawalit-pjk2011@hotmail.com tashibat@ncc.go.jp steve.rozen@duke-nus.edu.sg raluca.gordan@duke.edu.
Bin Tean TehProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore. gmstanp@duke-nus.edu.sg teh.bin.tean@singhealth.com.sg chawalit-pjk2011@hotmail.com tashibat@ncc.go.jp steve.rozen@duke-nus.edu.sg raluca.gordan@duke.edu.
Patrick TanProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore. gmstanp@duke-nus.edu.sg teh.bin.tean@singhealth.com.sg chawalit-pjk2011@hotmail.com tashibat@ncc.go.jp steve.rozen@duke-nus.edu.sg raluca.gordan@duke.edu.
National Cancer Centre Singapore · SGDuke-NUS Medical School · SGKhon Kaen University · THSingapore General Hospital · SGNational Cancer Research Institute · GBNational University of Singapore · SGChang Gung University · TWDuke University · USInstitutul Clinic Fundeni · ROYonsei University · KRAssistance Publique – Hôpitaux de Paris · FRChenzhou First People's Hospital · CNHospital de Câncer de Barretos · BRLos Alamos National Laboratory · USMassachusetts General Hospital · USSun Yat-sen University · CNThe University of Tokyo · JPUniversidade Federal de São Paulo · BRUniversity of Verona · IT
Funding
Statistical Methods for Cancer Clinical TrialsP01CA142538 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVIDIAN, MARIE, KOSOROK, MICHAEL R · 2010 to 2019
$21.3MData commons for 'omic, microscopy and analysis core facilitiesS10OD018164 · OD · DUKE UNIVERSITY · PI WRAY, GREGORY A. · 2014 to 2014
$598kNCI NIH HHS P01 CA142538NIH HHS S10 OD018164
Abstract
Cholangiocarcinoma (CCA) is a hepatobiliary malignancy exhibiting high incidence in countries with endemic liver-fluke infection. We analyzed 489 CCAs from 10 countries, combining whole-genome (71 cases), targeted/exome, copy-number, gene expression, and DNA methylation information. Integrative clustering defined 4 CCA clusters-fluke-positive CCAs (clusters 1/2) are enriched in
Indexed as
Bile Duct NeoplasmsCholangiocarcinomaCpG IslandsDNA MethylationEpigenomicsErb-b2 Receptor Tyrosine KinasesGene Expression Regulation, NeoplasticGene Regulatory NetworksGenome-Wide Association StudyHumansReceptor, Fibroblast Growth Factor, Type 2Tumor Suppressor Protein p53ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFGFR2 protein, humanReceptor, Fibroblast Growth Factor, Type 2TP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT04720131ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.